PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Absolute neutrophil count >= 1,000/mm^3, within 2 weeks prior to enrollmentXx_NEWLINE_xXAdequate Bone Marrow Function defined as:\r\n* Peripheral absolute phagocyte count (APC) > 1000/ µL; APC = numbers of banded neutrophils + segmented neutrophils + metamyelocytes + monocytes + eosinophils Please note, if institution reports differential as a percentage, then APC = [percentage of banded neutrophils + segmented neutrophils+ metamyelocytes+monocytes+eosinophils] x total white cell count.\r\n* Platelet Count > 100,000/µL (transfusion independent)\r\n* Hemoglobin > 8 gm/dL (may have received RBC transfusions)Xx_NEWLINE_xXCD4 count >= 50 cells/ulXx_NEWLINE_xXAnti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollmentXx_NEWLINE_xXAbsolute lymphocyte count (ALC) ? 500/mm3Xx_NEWLINE_xXNOTE: Patients with documented bone marrow involvement by lymphoma are not required to meet the above hematologic parameters, but must have a platelet count of at least 75,000/mcL and neutrophil count of at least 1,000/mcLXx_NEWLINE_xXAbsolute granulocyte count (AGC) >= 1,500/mm^3, within 4 weeks of randomizationXx_NEWLINE_xXAnti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agentXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL (unless documented bone marrow involvement with lymphoma)Xx_NEWLINE_xXHematology: Absolute neutrophil count (ANC) >1,500 cells/mm3, platelet count >100,000 cells/ mm.cu. and hemoglobin > 9 g/dLXx_NEWLINE_xXAbsolute granulocyte count >= 1.2 x 10^3/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1.5 × 10e3/µLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,000 cells/mm3 (1.0 x 109/L)Xx_NEWLINE_xXInadequate hematologic function (unless due to underlying lymphoma), defined as follows: Hemoglobin less than (<) 9 grams per decilitre (g/dL), absolute neutrophil count (ANC) <1.5*10^9 cells per liter (cells/L), platelet count <75*10^9 cells/LXx_NEWLINE_xXGranulocyte 1500 cells/mm3Xx_NEWLINE_xXAbsolute myeloblast count ?20,000/mm^3;Xx_NEWLINE_xXAbsolute neutrophil count (ANC) at least 1,000/mm3Xx_NEWLINE_xXAny of the following clinical laboratory values at the time of enrollment: (1) Absolute neutrophil count (ANC) <800/µL or (2) Platelets < 50,000/µLXx_NEWLINE_xXAdequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ?1500 cells/mm3, Platelet count ?100 x 109/L, Hemoglobin (Hgb) ?10 g/dLXx_NEWLINE_xXAbsolute lymphocytes count ? 800 cells/mm3Xx_NEWLINE_xXTotal lymphocyte count >= 0.5 x 10^9/LXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uL for subjects with bone marrow involvement; these subjects will not be evaluable for hematologic toxicity or hematologic dose limiting toxicity (DLT), but will be subject to dose modifications based on hematologic criteriaXx_NEWLINE_xXabsolute neutrophil count (ANC) ? 1.5 x 109/L and platelet count ?100 x 109/LXx_NEWLINE_xXSerum hemoglobin ? 9 g/dL; absolute neutrophil count ? 1.5 x 109/L; platelets ? 100 x 109/L.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 10e9/L) (growth factor cannot be used within the previous 7 days)Xx_NEWLINE_xXPlatelet count > 50,000 cells/dL (50 x 10e9/L)Xx_NEWLINE_xXHematology Hemoglobin ? 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3 Absolute neutrophil count (ANC) < 1500/mm3Xx_NEWLINE_xXHematologic: Absolute neutrophil count (ANC) ?1.5 x 10^9/liter (L), platelets ? 100 x 10^9/L, and hemoglobin ? 8 gram/deciliter (g/dL).Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) <400/µL.Xx_NEWLINE_xXHas adequate bone marrow function, defined as: Platelet count >= 100 x 109/L Hemoglobin >= 9.0 g/dL Absolute neutrophil count >= 1.5 x 109/L.Xx_NEWLINE_xXPIK3CA WILD TYPE COHORT (closed 03/17/2016): Absolute neutrophil count >= 1,500/mcLXx_NEWLINE_xXAdditional Laboratory Requirements ANC ?1.0 x 109/L Hgb ?8 g/dL(transfusion permitted) Platelet count ?50.0 x 109/LXx_NEWLINE_xXAbsolute neutrophil count (ANC) <2,000/mm3Xx_NEWLINE_xXSubjects must have hematologic and renal functions as specified: Absolute neutrophil count ? 1500/mm3, platelets ? 100,000/mm3, Hgb ? 9.0g/dL, creatinine ? 1.7mg/dL, total bilirubin ? 1.5mg/dL, blood urea nitrogen (BUN) within 2 times the upper limit of normal, transaminases ? 4 times above the upper limits of the institutional norm.Xx_NEWLINE_xXAbsolute neutrophil count >= institutional lower limitXx_NEWLINE_xXHave a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #3 above)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uL if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); a subject will not be excluded because of pancytopenia >= grade 3 if it is due to disease, based on the results of bone marrow studiesXx_NEWLINE_xXEXPANDED ACCESS COHORT: Absolute neutrophil count >= 1,000/mcLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/mm^3 \r\n* Exception: unless documented bone marrow involvement by lymphomaXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/microliters, completed within 14 days prior to the date of registrationXx_NEWLINE_xXAt least one cytopenia (ANC < 1800/µL or platelet count < 100,000/µL or hemoglobin [Hgb] < 10 g/dL)Xx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Absolute neutrophil count: >= 1.5 x 10^9/L (1500/mm^3) within 2 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Absolute neutrophil count: >= 1.5 x 10^9/L (1500/mm^3) within 2 weeks of registrationXx_NEWLINE_xXPeripheral blast count of <10%Xx_NEWLINE_xXBone marrow reserve consistent with: absolute neutrophil count ? 1.5 x 109/L, platelet count ? 100 x 109/L, and hemoglobin ? 9 g/dL (without transfusion) within 1 week preceding the administration of the study drugs;Xx_NEWLINE_xXAdequate bone marrow function (hemoglobin [Hb] ? 9.0 g/dL [subjects may be transfused to Hb ? 9.0 g/dL]; platelets ? 100 × 109cells/L; absolute neutrophil count [ANC] ? 1.5 × 109 cells/L without the use of hematopoietic growth factors).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) <1,500/mm3, pre-transfusion platelets <100,000/mm3, or pre-transfusion hemoglobin <9.0 mg/dL (the patient is required to have at least 2 weeks free from blood transfusion, G-CSF and erythropoietin use prior to the hematology test)Xx_NEWLINE_xXAbsolute neutrophil count ?1,000/mm3 without growth factor use ? 7 days prior to treatment (cycle 1 day 1, C1D1)Xx_NEWLINE_xXAbsolute neutrophil count ? 1.5 × 109/L (without myeloid growth factors within 1 week of study entry)Xx_NEWLINE_xXAbsolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >500/µLXx_NEWLINE_xXAbsolute neutrophil count ? 1.5 x 10?/Liters (L) (1500/cubic millimeters)Xx_NEWLINE_xXAdequate organ function defined as absolute neutrophil count ?1,500×10^6/L, absolute lymphocyte count ?500/mm^3, and platelet count ?100,000×10^6/mm^3. Adequate liver function defined as aspartate aminotransferase and alanine aminotransferase ?2.5× the upper limit of institutional normal, bilirubin ?1.5 mg/dL or 25 µmol/L. Adequate renal function defined as blood urea nitrogen and serum creatinine of ?1.5 mg/dL or 130 µmol/L.Xx_NEWLINE_xXANC ? 1,000/?LXx_NEWLINE_xXabsolute Neutrophil Count (ANC) ? 1500 mm3, platelets ? 100,000/mm3, hemoglobin ? 9 g/dL,Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXPlatelet count ? 100 × 109/L, hemoglobin ? 9.0 g/dL and absolute neutrophil count (ANC) ? 2.0 × 109 /L.Xx_NEWLINE_xXAbsolute peripheral blood myeloblast count greater than 20,000/mm3Xx_NEWLINE_xXAdequate organ function within 14 days of study registration including:\r\n* Absolute lymphocyte count (ALC) >= 0.5 x 10^9/LXx_NEWLINE_xXAbsolute neutrophil count ? 1,500. Blood transfusion to meet the inclusion criteria not be allowed.Xx_NEWLINE_xXPlatelet count > 100000 /mm3, hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) 1500/mm3; the patient cannot be transfused in order to meet study entry criteriaXx_NEWLINE_xXIn addition to the pathologic diagnosis, at least ONE of the following cytopenias must be present:\r\n* Hemoglobin < 11 g/dL within 14 days of registration; this includes patients with transfusion dependency\r\n** NOTE: transfusion dependency at screening is defined for this protocol as 1-8 disease-related units red blood cells (RBC) transfused in the previous 8 weeks; patients receiving more than 8 disease-related units of RBCs within 8 weeks of registration are excluded\r\n* Platelet count must be ? 20,000/mm^3 and < 100,000/mm^3 within 14 days of registration\r\n* Absolute neutrophil count (ANC) < 1000/mm^3 within 14 days of registrationXx_NEWLINE_xXANC >500/mm3.Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 500/ mm^3Xx_NEWLINE_xXPatients with a peripheral blood total lymphocyte count of higher than 25,000/mm3 may not be enrolled.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2\r\n* If a patient’s bone marrow function falls below the indicated values and it is not thought to be related to prior treatments a hematology consult will be ordered; if hematology deems the patients safe to proceed with treatment they will be allowed to enroll on study; in such cases, the patient’s absolute neutrophil count must be > 1,000/mcl, hemoglobin must be > 7.5 g/dL and the platelet count must be > 75,000 mcL; each patient will also be seen by a medical oncologist at follow-up visits if possibleXx_NEWLINE_xXAbsolute neutrophil count > 1000 /uL unless due to heavily infiltrated bone marrow (> 80% CLL cell infiltrate)Xx_NEWLINE_xXAbsolute neutrophil count >= 750 prior to treatmentXx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 100 cells/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/dLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >1,800 cells/mm3.Xx_NEWLINE_xXPART I: Absolute lymphocyte count (ALC) >= 300 cells/mm^3Xx_NEWLINE_xXANC >/= 800/mm3, Cohort 8 (PTCL): ANC >/= 1000/mm3Xx_NEWLINE_xXCD4 lymphocyte count or other T lymphocyte subset count will not be used to determine eligibilityXx_NEWLINE_xXT-LGL judged by the investigator to require therapy based upon:  \r\n*Severe neutropenia (absolute neutrophil count < 500/microL)\r\n*Moderate neutropenia (absolute neutrophil count < 1000/microL) with recurrent infections\r\n*Symptomatic or transfusion dependent anemia\r\n*Severe thrombocytopenia (< 50,000/microL)\r\n*Hepatic infiltration resulting in abnormal liver function tests\r\n*Symptomatic splenomegalyXx_NEWLINE_xXAbsolute lymphocyte count (ALC) of > 5,000 K/uLXx_NEWLINE_xXLymphocyte count >= 300/uL.Xx_NEWLINE_xXAt time of registration and within 4 weeks prior to initiating on-protocol treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L\r\n* May be waived on a case-by-case basis for patient populations recognized to have normal baseline values below this level.Xx_NEWLINE_xXLymphocyte count >= 0.5 × 10^9/L.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,000 cells/mm3 (1.0 x 109/L) (Growth factors cannot be used within 10 days (14 days for pegfilgrastim) prior to initiation of therapy)Xx_NEWLINE_xXCD4 gene count > 200/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support, obtained =< 14 days prior to registrationXx_NEWLINE_xXLymphocyte count >= 0.5 x 10^9/LXx_NEWLINE_xXNeutrophil count of more than or equal to 1.0 x 10^9 cells/mcLXx_NEWLINE_xXLymphocyte count >= 0.5 x 10^9/L (in absence of blood transfusion).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ?750 cubic millimeters (mm³)Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) ? 300/mm^3, and absolute number of CD3+ T cells > 150/mm^3Xx_NEWLINE_xXAdequate hematologic function as indicated by i. Absolute neutrophil counts (ANC) ? 1,500/mm3 ii. Hemoglobin (Hgb) ? 8.0 g/dL iii. Platelet count ? 100,000/mm3Xx_NEWLINE_xXLymphocyte count >= 300/uL.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/mm^3 independent of growth factor supportXx_NEWLINE_xXAbsolute granulocyte count < 1000; platelets <100,000.Xx_NEWLINE_xXAbsolute lymphocyte count >= 500/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXGranulocyte count >= 1000/mm3 ((within 16 days before starting therapy)Xx_NEWLINE_xXCD4 count > 200/uLXx_NEWLINE_xXWithin 10 days of treatment initiation: Hematological\r\n* It is anticipated that refractory AML patients will have low hematological counts including platelet count, hemoglobin, and absolute neutrophil count. Thus, hematologic parameters will not be used for enrollment and initiation of treatmentXx_NEWLINE_xXWithin 10 days prior to on-study date: Absolute lymphocyte count ? 500/mm^3Xx_NEWLINE_xXAbsolute lymphocyte count ? 400/mm^3 within 10 days prior to “on study” statusXx_NEWLINE_xXHemoglobin ?4.0 g/dL. Absolute neutrophil count ?1.0 x 109/L and platelet count ?75 x 109/LXx_NEWLINE_xXWithin 7 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (unless due to bone marrow infiltration by tumor, in which case ANC > 1,000/mm^3 is allowed).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/mm^3 (1.0 x 10^9/L) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uL\r\n* If these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of pancytopenia >= grade 3 if it is due to disease, based on the results of bone marrow studiesXx_NEWLINE_xXAbsolute lymphocyte count >= 800/mcLXx_NEWLINE_xXSubjects not below specific total neutrophil count.Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 0.8 x 10^9/L.Xx_NEWLINE_xXLymphocyte count >= 300/uLXx_NEWLINE_xXLymphocyte count >= 300/uLXx_NEWLINE_xXhave adequate hematologic function, defined as having a hemoglobin ?8g/dL, an absolute neutrophil count (ANC) ?1.0 × 109/L, and platelet count ?75.0 x 109/L;Xx_NEWLINE_xXAbsolute neutrophils > 1,500/µLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/microliterXx_NEWLINE_xXAT SCREENING: Absolute neutrophil count within institutional normal limits. Administration of growth factors or blood transfusions will not be allowed to confirm eligibility.Xx_NEWLINE_xXAT SCREENING: Absolute lymphocyte count within institutional normal limits. Administration of growth factors or blood transfusions will not be allowed to confirm eligibility.Xx_NEWLINE_xXAbsolute neutrophil count >= 1,500 cells/mm^3 based on complete blood count (CBC)/differential within 14 days prior to Step 2 registrationXx_NEWLINE_xXCompromised hematopoietic function (hemoglobin <8.0 g/dL; lymphocyte count <300 mm3; neutrophil count <1000 mm3; platelet count <100,000 mm3).Xx_NEWLINE_xXPatients must have adequate organ and bone marrow function within 14 days prior to registration, as defined by: absolute neutrophil count >= 1,500/mcL, regardless of transfusion or growth factor supportXx_NEWLINE_xXPatients without evidence of documented disease progression clinically or radiographically after ASCT (stable disease [SD], partial remission [PR] or complete remission [CR]) who have had count recovery (absolute neutrophil count [ANC] > 500 cells/mm^3, non-transfused platelet count > 20,000 K/mm^3) and are at least 30 days post ASCT but no more than 120 days post ASCTXx_NEWLINE_xXPatients with lack of count recovery as defined by ANC > 500 cells/mm^3, non-transfused platelet count > 20,000 K/mm^3Xx_NEWLINE_xXPatients should have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea or similar agent is allowed)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testingXx_NEWLINE_xXAbsolute lymphocyte count (ALC) >1000 cells/mm3Xx_NEWLINE_xXPlatelets > 100,000 cells/mm3 and absolute neutrophil count (ANC) > 1,250 cells/mm^3Xx_NEWLINE_xXGranulocyte count <1500/mm3Xx_NEWLINE_xXANC ? 1.5 x 109/LXx_NEWLINE_xXAdequate bone marrow function: white blood cells (WBCs) ? 3,000/mm3, absolute neutrophil count (ANC) ? 1,500/mm3, hemoglobin ? 9 g/dL, and platelets ? 100,000/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/mm^3 without transfusion or growth factor support for at least 1 weekXx_NEWLINE_xXDetermined within 3 weeks of treatment initiation: Absolute neutrophil count >= 1,000/mm^3 (1.0 x 10^9/L)Xx_NEWLINE_xXAbsolute granulocyte count < 1000; platelets <100,000.Xx_NEWLINE_xXGranulocyte count >= 1,500/mm^3 (within 16 days of enrollment)Xx_NEWLINE_xXSufficient bone marrow capacity as defined by WBC (white blood cell ) ?2.500/?l, PLT (platelet) count ?100.000/?l, Hb?9.9 g/dl and ANC?1500 mm3 for the first cycle and WBC?2.000/ ?l,PLT count ?75.000/?l, Hb?8.9 g/dl and ANC?1000 mm3 for the subsequent cyclesXx_NEWLINE_xXAbsolute lymphocyte count >= 500/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXLymphocyte count >= 300/uLXx_NEWLINE_xXCD4 count >= 100 in the dose-finding cohort; once the dose-finding cohort is complete and if safety is established, participants with any CD4 count, including CD4 count < 100, will be allowed in the dose-escalation phaseXx_NEWLINE_xXAbsolute neutrophil count: >= 1,000/mm^3, unless decreased due to bone marrow involvement with lymphomaXx_NEWLINE_xXAdequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, ANC > 1,500 per mm3, platelets > 100,000 per mm3).Xx_NEWLINE_xXBone marrow reserve consistent with absolute neutrophil count (ANC) >= 1500 per micro liter (/mcL); platelet count >= 100,000/mcL; hemoglobin A1c (HbA1c) less than (<) 6.5 percent (%).Xx_NEWLINE_xXObtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor supportXx_NEWLINE_xXPatients with HCL must be intolerant of or not candidates for purine analog-based therapy, or failed to achieve response (CR or partial response [PR]) or relapsed within 2 years of such therapy, AND meet the standard treatment initiation criteria (absolute neutrophil count [ANC] =< 1000/uL, hemoglobin [Hgb] =< 10 g/dL, platelet count =< 100,000/uL); patients with indolent lymphoma (FL, LPL, MZL) and patients with B-cell prolymphocytic leukemia must have an indication for treatment in the opinion of the investigator; patients with MCL and patients with CLL in Richter’s transformation should have previously received or not be candidates for high dose chemotherapy/autologous stem cell transplantXx_NEWLINE_xXHematology: Haemoglobin ? 9.0 g/dl; ANC ? 1.5 × 109/L; Platelet count ? 100 × 109/LXx_NEWLINE_xXDONOR: Complete blood count (CBC) with differential and platelet count within normal limits, as deemed acceptable by the principal investigatorXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL (without growth factor support)Xx_NEWLINE_xXAdequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ?1500 cells/mm3, Platelet count ?100 x 109/L, Hemoglobin ?10 g/dL; subjects with thalassemia having a hemoglobin <10 g/dL may be enrolled, per Investigator discretionXx_NEWLINE_xXAplastic anemia with absolute neutrophil count (ANC) < 1,000 and transfusion dependent after failed immunosuppression therapyXx_NEWLINE_xXAbsolute neutrophil count > 1800 cells/cubic mmXx_NEWLINE_xXAbsolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/dLXx_NEWLINE_xXAbsolute lymphocyte count >= 400/uLXx_NEWLINE_xXNeutrophil count of >= 1.0x 10^9 cells/LXx_NEWLINE_xXNo cytopenias (defined as platelets <100,000/mm3, hemoglobin <10 g/dL, or absolute neutrophil count <1,500/mm3).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000/mm^3 (Unit of International System of Units [SI] units 109/L)Xx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/mm^3, with or without transfusion support; NOTE: If the patient’s bone marrow biopsy shows greater than or equal to 50% plasma cells, absolute neutrophil count (ANC) > 500 cells/mm^3 (transfusion support or growth factor support is acceptable)Xx_NEWLINE_xXBone marrow reserve consistent with: absolute neutrophil count (ANC) >= 1.5 x 10^9/L values must be obtained without the need for myeloid growth factor support, platelet or packed red blood cell (PRBC) transfusion support within 14 daysXx_NEWLINE_xXAdequate hematologic function (Platelets ? 60,000/mm3, lymphocytes ? 1,000/mm3, neutrophils ? 750/mm3, hemoglobin ? 10 g/dl).Xx_NEWLINE_xXSubjects with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal disease (estimated glomerular filtration rate (eGFR) <30ml/min), hepatic (Alanine transaminase (ALT) 2.5 times upper limit of normal (>2.5xULN), bilirubin > 2x ULN), hematological (absolute neutrophil count (ANC) <1.0 x 109/L, platelet count <75x109/L or requires regular platelet transfusions to maintain a platelet count ? 75 x 109/L , hemoglobin <9g/dL), endocrine (glycated Haemoglobin (HbA1c)>7% or random glucose >200mg/dL), pulmonary (Forced Expiratory Volume in 1 second (FEV1) <70% of predicted value), cardiac (New York Heart Association (NYHA)) class III/IV, or neurological diseaseXx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 500/mm^3Xx_NEWLINE_xXHemoglobin ? 9.0 g/dl, absolute neutrophil count (ANC) ? 1,500 cells/µl, platelets ? 125,000 cells/µlXx_NEWLINE_xXabsolute neutrophil count ? 1.5x10^9/LXx_NEWLINE_xXSmall lymphocytic lymphoma with absolute lymphocyte count <5x10E9/L at study entryXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mm^3 without growth factor use =< 7 days prior to C1D1Xx_NEWLINE_xXRecovery from last induction course of chemotherapy (absolute neutrophil count [ANC] > 500 and platelet > 20,000)Xx_NEWLINE_xXContraindications to TAS-102\r\n* Absolute neutrophil count < 1,500/ul\r\n* Platelet count < 75,000/ul\r\n* Allergy or intolerance to TAS-102Xx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Absolute neutrophil count >= 1,000/mm^3Xx_NEWLINE_xXBone marrow: hemoglobin ? 10 g/dL, platelet count ? 100,000/mm3, absolute neutrophil count ? 1,500/ mm3, absolute lymphocyte count ? 500/ mm3.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) of < 1.5×109/L, or platelet count of < 100 ×109/L, or hemoglobin < 9g/dL;Xx_NEWLINE_xXAdequate hematological function, defined as ANC ? 1,500/mm3, Hb ? 9.0 g/dL, and platelet count ? 100,000/mm3.Xx_NEWLINE_xXLymphocyte count >= 300/uLXx_NEWLINE_xXBone marrow impairment as evidenced by hemoglobin <10.0 g/dL, neutrophil count <1.0 × 109/L, platelets <100 × 109/LXx_NEWLINE_xXLymphocyte count > 1,000/mcLXx_NEWLINE_xXAbsolute CD4 count > 200 cells/uLXx_NEWLINE_xXANC ? 1,000/?LXx_NEWLINE_xXPatient must have no persistent toxicities from prior therapy >= grade 2 with the exception of\r\nhematologic indices (i.e., hemoglobin, white blood cell count [WBC], ANC, absolute lymphocyte count [ALC])Xx_NEWLINE_xXAbsolute lymphocyte count ? 100/µLXx_NEWLINE_xXAdequate bone marrow function as defined below: \r\n• Absolute neutrophil count ? 1.5x109 /L (1500 per mm3) \r\n• Platelets ? 100x109 /L (100,000 per mm3) \r\n• Hemoglobin > 9.0 g/dLXx_NEWLINE_xXPatients with adequate organ function, reflected by the following parameters: WBC ? 3000/mcl Absolute neutrophil count (ANC) ? 1500/mcl Platelet count ? 100,000/mcl SGOT, SGPT, and alkaline phosphatase ? 2.5 X upper limit of normal (ULN) Bilirubin ? 1.5 X ULN Creatinine ? institutional ULNXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nAbsolute neutrophil count >= 1,500/mcLXx_NEWLINE_xXHematological - Absolute neutrophil count (ANC) ? 1.5 x 109/L (Carboplatin Plus Paclitaxel Arm or Paclitaxel Arm) or ? 1.0 x 109/L (Anastrozole Arm)Xx_NEWLINE_xXPeripheral blood (PB) showing at least two of the following criteria: Absolute neutrophil count (ANC) < 0.5 k/µL Platelet count < 30 k/µL Absolute reticulocyte count < 60,000/µLXx_NEWLINE_xXMarrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3 platelets ?100,000/mm3, absolute lymphocyte count ?1000/mm3.Xx_NEWLINE_xXAbsolute lymphocyte count < 200/ mm^3Xx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Absolute lymphocyte count >= 500/mm^3Xx_NEWLINE_xXFor subjects with solid tumors without known bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 750/mm^3Xx_NEWLINE_xXSmall lymphocytic lymphoma(SLL) with absolute lymphocyte count <5x10*9/L at study entryXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 x 10^9 cells/L (growth factor use is allowed)Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 100 cells/ulXx_NEWLINE_xXHematology: . Absolute neutrophil count ? 1.5 x 109/L or ? 1,500/µl Platelets ? 100 x 109/L or ? 100,000/µlXx_NEWLINE_xXWithin 30 days of first vaccination: Lymphocyte count >= 800/mm^3Xx_NEWLINE_xXResearch participant’s absolute leukemic blast count does not exceed 10,000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,200/mcL (subjects may be treated with hematopoietic growth factors to achieve or maintain this level)Xx_NEWLINE_xXA. Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3, platelets ?75,000/mm3, absolute lymphocyte count ?475/mm3.Xx_NEWLINE_xXGranulocyte count >= 1,500/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 x 10^9/L or < 1.0 x 10^9/L but >= 0.75 due to > 30% marrow involvement\r\n* Patients who entered the trial prior to June 4, 2014 were restricted to > 50% marrow involvementXx_NEWLINE_xXAbsolute granulocyte count (AGC) >= 1,500Xx_NEWLINE_xXHave serum creatinine <1.6 mg/dL, INR < 1.5 U, absolute neutrophil count (ANC) > 1 x 109/L , platelets ? 100 x 109/L , hemoglobin ? 10 mg/dL, ALT and AST ? 3 x ULN, bilirubin ? 1.5 x ULNXx_NEWLINE_xXAbsolute neutrophil count more or equal to 750/mLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXAbsolute neutrophil count < 1,500/?L, platelet count < 100,000/?L, or hemoglobin < 6.2 mmol/L (10 g/dL) at screeningXx_NEWLINE_xXPatients must have a platelet count > 100,000/µL, hemoglobin ? 10.0 gm/dL, white blood cell count (WBC) > 2,000/uL, absolute neutrophil count (ANC) ? 1.5 x 109/L, and a serum creatinine ? 1.5 mg/dL unless the measured creatinine clearance is > 40 mL/min/1.73 m2.Xx_NEWLINE_xXAbsolute lymphocyte count < 0.5 x 10^9/LXx_NEWLINE_xXHave a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #5 above)Xx_NEWLINE_xXAbsolute neutrophil count >= 750 cells/mm^3 (0.75 x 10^9/L), at screeningXx_NEWLINE_xXBlast count =< 10,000Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000 microliterXx_NEWLINE_xXAbsolute lymphocyte count (ALC) > 500Xx_NEWLINE_xXAbsolute neutrophil count < 1500 per mm3 or platelet count < 100,000 per mm3 if getting chemotherapy concurrent with radiationXx_NEWLINE_xXAbsolute lymphocyte count >= 500/cu mmXx_NEWLINE_xXTreatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment, if applicable:\r\n* Neutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)\r\n* Anemia (hemoglobin [Hgb] < 10g/dL)\r\n* Thrombocytopenia (platelets [Plt] < 100,000/ul)\r\n* Absolute lymphocyte count (ALC) of > 5,000 cells/uL\r\n* Symptomatic splenomegaly\r\n* Enlarging lymph nodes > 2 cm\r\n* Repeated infections requiring oral or i.v. antibioticsXx_NEWLINE_xXPatients must have absolute lymphocyte counts (ALC) of more than 5,000 cell/mm^3Xx_NEWLINE_xXHematopoietic Function: WBC ? 2,500/mm3; ANC ? 1000/mm3; Hemoglobin ? 8 g/dL; Platelet count ? 50,000/mm3; Coagulation: INR ? 1.3.Xx_NEWLINE_xXPatients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3 and platelet count of >/= 100,000 cells/mm3;Xx_NEWLINE_xXLaboratory test results within these ranges: Absolute neutrophil count ? 1.0 x 109/L, Platelet count ? 50 x 109/L, Serum creatinine ? 1.5 mg/dL, Total bilirubin ? 1.5 mg/dL, AST & ALT ? 2 x ULNXx_NEWLINE_xXAbsolute granulocyte count > 1.5 x 10^3/mm3Xx_NEWLINE_xXBone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3.Xx_NEWLINE_xXAbsolute granulocyte count >= 1.2 x 10^3/mm^3Xx_NEWLINE_xXAnticancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil count [ANC] counts): ?7 days after the last dose of agent.Xx_NEWLINE_xXANC ? 1.5 x 109/LXx_NEWLINE_xXAbsolute lymphocyte count (ALC) > 800/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) ?750 cells/mm3 (1.0 x 109/L)Xx_NEWLINE_xXAdequate hematologic function (Platelets ? 60,000/mm3, lymphocytes ? 1,000 mm3, neutrophils ? 750/mm3, hemoglobin ? 9.0 g/dl).Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL; platelets ? 100 x 109/L; absolute neutrophil count ? 1.5 x 109/L without the use of hematopoietic growth factorsXx_NEWLINE_xXANC < 1000 cells/mm3 or < 750 cells/mm3 due to >50% marrow involvementXx_NEWLINE_xXAdequate hematologic reserve obtained ? 2 weeks prior to entry: leukocytes ? 3,000 mm^3; absolute neutrophil count ? 1500 mm^3; platelets ? 100,000 mm^3Xx_NEWLINE_xXAdequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, ANC > 1,500 per mm3, platelets > 100,000 per mm3).Xx_NEWLINE_xXANC > 1500/mm3, plt count > 100,000/mm3Xx_NEWLINE_xXHematology: ANC >1500 cells/mm3, platelet count >100,000 cells/mm3 and Hemoglobin > 9 gm/LXx_NEWLINE_xXAbsolute granulocyte count of ?1,000/?L, platelet count ?50,000/?L, and hemoglobin ?8.0 g/dL, with no transfusion within the preceding 7 daysXx_NEWLINE_xXAdequate organ function as defined by the following criteria: Absolute neutrophil count (ANC) ? 1500/?l, Platelets ? 140,000/?l,Hemoglobin ? 12.0 g/dl, Creatinine < 2.0 mg/dlXx_NEWLINE_xXANC ? 1.0 x 109/LXx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 500/mm^3Xx_NEWLINE_xXBone marrow function: absolute neutrophil count ?1,500/µL, and platelets ? 100,000/ µL;Xx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: absolute neutrophil count (ANC) >= 1,000/mm^3\r\n* NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement\r\n* Exception: Unless documented bone marrow involvement by lymphomaXx_NEWLINE_xXLymphocyte count ? 0.5 x 109/L (500/µL)Xx_NEWLINE_xXAdequate hematology without ongoing transfusional support (hemoglobin > 8 g/dL, ANC ? 1,500 per mm3, platelets > 100,000 per mm3)Xx_NEWLINE_xXAbsolute T-cell count (ATC) at screening >= 0.07 K/microL. This is defined as CD3+ T-cell percent (expressed as fraction of 100%) multiplied by the absolute lymphocyte count (ALC, expressed in K/microL).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1.5x10^9/L for paclitaxel cohort, and ? 1.0x10^9/L for endocrine therapy cohortXx_NEWLINE_xXFor subjects with solid tumors without known bone marrow involvement: \r\n*Peripheral absolute neutrophil count (ANC) ? 750/mm^3Xx_NEWLINE_xXPlatelets >= 50,000/mm^3 independent of transfusion support, with no active bleeding, and absolute neutrophil count >= 1000/mm^3, unless due to disease involvement in the bone marrowXx_NEWLINE_xXWithin 14 days prior to day 1 of protocol therapy unless otherwise stated: Absolute neutrophil count (ANC) >= 1,000/mm^3\r\n* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvementXx_NEWLINE_xXAbsolute lymphocyte count > 1,000/mm^3Xx_NEWLINE_xXPatients with very low CD4 counts (< 200/uL or 14% of total lymphocyte count)Xx_NEWLINE_xXAdequate hematologic function: Absolute neutrophil count (ANC) ? 1.0 109/L, platelet count ? 100.0 109/L and hemoglobin ? 8.0 g/dL (patients with bone marrow involvement will not be evaluable for hematologic DLT and can enroll with ANC ? 0.75 109/L, platelet count ? 50.0 109/L and hemoglobin ? 8.0 g/dL)Xx_NEWLINE_xXThe absolute neutrophil count (ANC) must be > 1000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recoverXx_NEWLINE_xXAbsolute granulocyte count >= 1.0 x 10^3/mm^3Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 800/uLXx_NEWLINE_xXPeripheral granulocyte count of > 1,500/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ?1.0 x 109 /L, hemoglobin ?8 g/dL, and platelet count ? 75 x 109/L.Xx_NEWLINE_xXAbsolute granulocyte count (AGC) >= 1,500 cells/mm^3Xx_NEWLINE_xXLymphocyte count >= 400/mm^3Xx_NEWLINE_xXSecondary Registration: absolute lymphocyte count >= 200/uLXx_NEWLINE_xXAbsolute lymphocyte count >= 800/mcLXx_NEWLINE_xXAbsolute neutrophil count >= 750 cells/mcL (0.75 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL (without hematopoietic growth factors)Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uL\r\n* If the ANC and/or platelet count are not adequate, but due to bone marrow metastatic disease, these criteria will be waivedXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support within 14 days prior to registrationXx_NEWLINE_xXSubject has circulating blast count > 50,000/?L (subjects may be enrolled if circulating blast count is controlled by hydroxyurea and/or, if clinically indicated, by leukophoresis)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 750/uL, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) must be > 750/mm^3 (unless due to underlying disease in which case there is no grade restriction)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL assessed within seven (7) days prior to the start of therapyXx_NEWLINE_xXAbsolute CD4 count of < 50 cells/ mm^3Xx_NEWLINE_xXAbsolute lymphocyte count of > 20,000 cells/ul or symptomatic splenomegalyXx_NEWLINE_xXANC ?1,000/mm^3 (?1.0 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count ?1.5 × 10^9/liter (L), platelets ?100 × 10^9/L, and hemoglobin ?9 grams/deciliter (5.58 millimoles/L).Xx_NEWLINE_xXPlatelet count ?20,000/µL (Transfusions to achieve this level are allowed).Xx_NEWLINE_xXAdequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ? 1.5 x 109/L, platelet count ?100 x 109/L, hemoglobin >9.0 g/dL. For Portion B: ANC ? 1.0 x 109/L, platelet count ? 75 x 109/L, and hemoglobin ? 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.Xx_NEWLINE_xXInadequate bone marrow function per protocol-specified hemoglobin, platelet count, and absolute neutrophil countXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000 cells/mm^3 within 21 days of initiation of protocol therapy; growth factor administration is not allowed to meet ANC eligibility criteriaXx_NEWLINE_xXPlatelet count < 50 x10^9/L or absolute neutrophil count (ANC) < 1 x10^9/L at the Screening visitXx_NEWLINE_xXPatient must have adequate bone marrow function as evidenced by absolute neutrophil count ?1.5 ×10^9/L; hemoglobin >9 g/dL (Patients are allowed to be transfused to this level); platelets ?75 × 10^9/LXx_NEWLINE_xXPlatelet count ? 30,000 cells/?L without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded.Xx_NEWLINE_xXPlatelet count ? 50,000 cells/?L, or ? 30,000 cells/?L in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1.000/mm3Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) ? 300/mm3Xx_NEWLINE_xXMarrow: Peripheral blood leukocyte count (WBC) < 3000/mm3, absolute neutrophil count ? 1500/mm3, platelets < 75000/mm3, or hemoglobin < 10 gm/dLXx_NEWLINE_xXFor RCC, platelet count ?80,000 cells/mm3Xx_NEWLINE_xXFor urothelial carcinoma, gastric or GEJ adenocarcinoma, and CRC, platelet count ?100,000 cells/mm3Xx_NEWLINE_xXCD4+ T-cell count >= 100 cells/uLXx_NEWLINE_xXScreening laboratory assessments outside the following limits: Absolute neutrophil count (ANC) <1,000/?l (<1.0 x 109/L) Platelet count <100,000/?l (<100 x 109/L) Hemoglobin <9 g/dL Total bilirubin >1.5 x institutional upper limit of normal (ULN) (i n case of known Gilbert's syndrome, <2 x ULN is allowed) Creatinine Creatinine clearance <30 mL/min (as calculated by Cockcroft-Gault formula or Modification of Diet in Renal Disease [MDRD] formula)Xx_NEWLINE_xXMust have neutrophil count >1200/mm3 (1.2x109/L)Xx_NEWLINE_xXMeets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function laboratory values within 2 weeks prior to first dose of study drug.Xx_NEWLINE_xXHematologic: Platelets ? 100 x 10^9/L; Hemoglobin ? 9.0 g/dL; absolute neutrophil count (ANC) ? 1.5 x 10^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit)Xx_NEWLINE_xXAbsolute blast count (ABC) ? 40,000/mmXx_NEWLINE_xXABC count ? 40,000/mmXx_NEWLINE_xXMarrow: Peripheral blood leukocyte count (WBC) < 3000/mm3, absolute neutrophils count ? 1500/mm3, platelets < 75000/mm3, or hemoglobin < 10 gm/dL.Xx_NEWLINE_xXAbsolute granulocyte count (AGC) >= 1,500/mm³Xx_NEWLINE_xXANC: for patients with lymphoma ?750/mm3 (?0.75 × 10^9/L), for patients with advanced solid tumors ?1,000/mm3 (?1.0 × 10^9/L),Xx_NEWLINE_xXabsolute neutrophil count >750/µLXx_NEWLINE_xXAbsolute WBC count ? 15 × 109/L. AML Cohort:Xx_NEWLINE_xXProgressive lymphocytosis in the absence of infection, with an increase in blood Absolute Lymphocyte Count (ALC) >=50% over a 2-month period, or a lymphocyte doubling time (LDT) of <6 months (as long as initial ALC was >=30000/µl).Xx_NEWLINE_xXSubject has absolute neutrophil count < 1500/?L, platelet count < 100000/?L or hemoglobin < 10 g/dL (6.2 mmol/L).Xx_NEWLINE_xXANC ? 1,500 / mm3Xx_NEWLINE_xXMarrow: Peripheral blood leukocyte count (WBC) < 3000/mm3, absolute neutrophil count ? 1500/mm3, platelets < 75000/mm3, or hemoglobin < 10 gm/dLXx_NEWLINE_xXBlood counts at screening: haemoglobin ? 9.0 g/dl,absolute neutrophil count ? 1500/µl, platelet count ? 100,000/µl.Xx_NEWLINE_xXAbsolute neutrophil count < 1000/?L, platelet count < 100,000/?L, or hemoglobin < 10 g/dL (6.2 mmol/L) at screening;Xx_NEWLINE_xXHematological: Absolute neutrophil count ?1x10^9/L; Platelet count ?75x10^9/L;Hemoglobin ?8g/dLXx_NEWLINE_xXAdequate bone marrow function as assessed by absolute neutrophil count (ANC) ? 1500/mm3; hemoglobin ? 9.0 g/dL, and platelet count ? 100,000/mm3.Xx_NEWLINE_xXAbsolute Neutrophil count (ANC) ?1.0 x10?/L (without G-CSF support)Xx_NEWLINE_xXAny of the following laboratory abnormalities: Absolute neutrophil count(ANC) < 1,000/µL, Platelet count < 75,000/µL or < 50,000/µL for patients in whom ? 50% of bone marrow nucleated cells are plasma cells, Hemoglobin < 8 g/dL, Creatinine clearance < 45 mL/min according to Cockcroft-Gault formula. If creatinine clearance calculated from the 24 hour urine sample is ? 45 mL/min, patient will qualify for the trial, Aspartate transaminase (AST) or Alanine transaminase (ALT) > 3.0 × Upper Limited Normal (ULN), Serum total bilirubin > 2.0 mg/dL or > 3.0 × ULN for patients with hereditary benign hyperbilirubinaemia.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 0.75 x 10^3/uL without treatment with a myeloid growth factor within 3 days prior to first dose of IPXx_NEWLINE_xXBone marrow reserve: Absolute neutrophil count (ANC) ? 1.5 x 109/L. Platelets ? 100 x 109/L. Hemoglobin ? 9 g/dL.Xx_NEWLINE_xXAbsolute neutrophil count > 750 cells/mcL (0.75 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count ? 1,000 cells/dL (1.0 x 109/L)Xx_NEWLINE_xXWithin 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factor supportXx_NEWLINE_xXAbsolute Neutrophil Count (ANC) ? 1.5 x 109/L without growth factor support for 7 days (14 days if received pegfilgrastim).Xx_NEWLINE_xXPatients must have undergone autologous hematopoietic stem cell transplantation (AHCT) and achieved engraftment by day (D)60-180 as evidenced by absolute neutrophil count (ANC) > 1000/mcL and platelets (Plt) > 75,000/mcLXx_NEWLINE_xXHematologic: Platelets ? 100 x 109/L; Hemoglobin ? 9.0 g/dL; absolute neutrophil count (ANC) ? 1.5 x 10^9/L (without platelet transfusion or any granulocytic growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit)Xx_NEWLINE_xXScreening hematology values of the following: absolute neutrophil count ? 1000/?L, platelets ? 100,000/?L, hemoglobin ? 10 g/dL (without transfusion support);Xx_NEWLINE_xXHematological function: hemoglobin >9 g/dL; lymphocyte count >0.50 x 109/L; neutrophil count >1.5 x 109/L; platelet count >100 x 109/LXx_NEWLINE_xXB-Leukocyte count ?4.5 x10e9/LXx_NEWLINE_xXPlatelet count ? 100,000 /mm3, hemoglobin (Hb) ? 9 g/dL, absolute neutrophil count (ANC) ? 1500/mm3. Blood transfusion to meet the inclusion criteria will not be allowed.Xx_NEWLINE_xXAdequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000 cells/mm^3, ANC>1,000 cells/mm^3, hemoglobin>9.5g/dL, and platelet count >100,000 cells/mm^3Xx_NEWLINE_xXAbsolute lymphocyte count ? 800/?L before the first dose of CG0070Xx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1.5 x 109/LXx_NEWLINE_xXNeutrophil count ? 1,500/mm3Xx_NEWLINE_xXLymphocyte count ? 500/mm3Xx_NEWLINE_xXHematologic: Absolute neutrophil count (ANC) 1.5 x 109/liter (L), platelets 100 x 109/L, and hemoglobin 8 gram/deciliter (g/dL).Xx_NEWLINE_xXPatients with severe hematopoietic insufficiency, as defined by an absolute neutrophil count of less than 500/MuL, unless disease-related, and/or a platelet count of less than 30,000/MuL at time of screening for this protocolXx_NEWLINE_xXPeripheral blood blast count < 10%Xx_NEWLINE_xXThere is no specific platelet and absolute neutrophil count that will exclude patients from this study given the natural history of AMLXx_NEWLINE_xXAbsolute neutrophil count >= 1,300/microliterXx_NEWLINE_xXParticipant has adequate hematological functions [absolute neutrophil count (ANC) ? 1500 cells/microliter (mcL), hemoglobin ? 9 grams/deciliter (g/dL), and platelets ? 100,000 cells/mcL and ? 850,000 cells/mcL]Xx_NEWLINE_xXLymphocyte count ? 300/µLXx_NEWLINE_xXWithin 14 days of enrollment: Lymphocyte count >= 300/mm^3Xx_NEWLINE_xXAbsolute Neutrophil Count* ? 1,500/mm3 (? 1.5 x 109/L)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1.5 × 10e3/µLXx_NEWLINE_xXAbsolute lymphocyte count (ALC) ? 1 × 10e3/µLXx_NEWLINE_xXAbsolute neutrophil count ? 1.5 x 106/µlXx_NEWLINE_xXHave a circulating blast count of less than 10,000/mm3 (control with hydroxyurea is allowed)Xx_NEWLINE_xXAbsolute lymphocyte count < 0.5 x 10^9/L (Phase 1 and Phase 2 Cohort A); absolute lymphocyte count < 1.0 x 10^9/L (Phase 2 Cohort B)Xx_NEWLINE_xXPeripheral blood blast count < 10,000/uLXx_NEWLINE_xXAbsolute neutrophil count > 1000/uL unless due to heavily infiltrated bone marrow (> 80% CLL cell infiltrate)Xx_NEWLINE_xXPatients with a diagnosis of CLL (any stage) with absolute lymphocyte count (ALC) >= 20 x 109/l, requiring therapyXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 x 10^9 /L, independent of growth factor support unless with bone marrow involvement for 14 daysXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcl unless in the opinion of the treating physician, neutropenia is due to splenomegaly or bone marrow involvementXx_NEWLINE_xXMarrow: Hemoglobin >= 10.0 g/dL, absolute neutrophil count (ANC) >=1,500/mm3, and platelets >=100,000/mm3.Xx_NEWLINE_xXWithin 28 days prior to signing informed consent: Absolute neutrophil count (ANC) >= 1,000/mm^3, independent of growth factor supportXx_NEWLINE_xXPlatelet count < 50 x109/L (< 50,000 cells/mm3)Xx_NEWLINE_xXHas adequate bone marrow function defined as a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) ?1.5 ×10?/L , and platelet count ?100,000/mm³. For subjects who received chemotherapy for melanoma just prior to screening for the study subject needs to have a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) >2 × 10?/L, and platelet count ?100,000/mm³.Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 250/uL obtained =< 7 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count 1.5 × 10^9/Liter (L), platelets 100 × 10^9/L, and hemoglobin 9 g/deciliter (dL) (5.58 millimoles/Liter).Xx_NEWLINE_xXNeutrophil count: ? 1.5 x 109/LXx_NEWLINE_xXSmall lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 10*9/L at the time of diagnosis and at study entry.Xx_NEWLINE_xXPeripheral granulocyte count of >= 1,500/mLXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 x 10^9 cells/L (growth factor use is allowed)Xx_NEWLINE_xXPreviously untreated subjects that meet ANY of the following criteria:\r\n* Subjects that refuse to be treated with chemotherapy based agents (this should be documented in the consent form)\r\n* Subjects that are not candidates for treatment with chemotherapy agents based on ANY of the following:\r\n** ECOG performance status >= 2\r\n** Advance age (>= 65 years)\r\n** Cumulative Illness Rating Scale (CIRS score) >= 6\r\n** Cytopenias\r\n*** Hemoglobin (Hb) =< 100 g/L (10 g/dL)\r\n*** Platelet count =< 100 x 10^9/L (100,000/uL)\r\n*** Absolute neutrophil count (ANC) =< 1.5 x 10^9/L (1,500/uL)Xx_NEWLINE_xXAdequate organ function as determined by: i. Absolute neutrophil count ? 1.5 x 109/L (1,500/mm3) ii.Platelet count ? 100 x 109/L (100,000/mm3) iii.Hemoglobin ? 9.0 g/dL within first 2 weeks prior to first dose of investigational product iv.Calculated creatinine clearance* (CrCl) or 24 hour urine CrCl > 50 mL/min v.Total bilirubin ? 1.5× ULN; for subjects with documented/suspected Gilbert's disease, bilirubin ? 3× ULN vi.Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5× ULN vii.Serum Electrolytes within normal limitsXx_NEWLINE_xXPHASE II: If the patient had significant bone marrow involvement (bone marrow [BM] plasma cells >= 50%), a platelet count >= 30,000 mm^3 and absolute neutrophil count (ANC) >= 1000/mm^3 is requiredXx_NEWLINE_xXPatients with plasma cells > 50% of bone marrow nucleated cells, and platelets >= 30,000/uL will be permitted regardless of the baseline ANC, if it is felt to be related to active myeloma and if in the opinion of the investigator, growth factor support can result in improvement in the neutrophil count to greater than 1000/uL (including during screening period)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 0.75 x 109/L or platelet count < 50 x 109/L unless due to disease involvement in the bone marrow.Xx_NEWLINE_xXPeripheral blood blast count < 10%Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXPeripheral granulocyte count of >= 1500/mm³Xx_NEWLINE_xXMarrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3, platelets ?75,000/mm3, absolute lymphocyte count ?475/mm3.Xx_NEWLINE_xXANC < 0.75 x 109/L or platelet count < 50 x 109/L unless there is bone marrow involvement.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 × 10^9/L (without transfusion support and without hematological growth factor support within 2 weeks of cycle 1 day 1)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/dLXx_NEWLINE_xXANC < 1,000/µLXx_NEWLINE_xXSubject's absolute neutrophil count is < 1500/microliter (µL), platelet count is < 100,000/µL) or hemoglobin is < 5.6 millimoles(mmol)/liter (L) (9 grams (g)/deciliter (dL) at Screening.Xx_NEWLINE_xXPlatelet count greater than 50,000/mm3 within 8 weeks prior to initial cryoablation procedure.Xx_NEWLINE_xXAbsolute neutrophil count > 1200Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 x 10^9 /L. No transfusion or growth factor support for one week prior to labs.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator; transfusions and growth factors are permissibleXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL in the absence of growth factor administrationXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/m^3 (no transfusion within 7 days of enrollment)Xx_NEWLINE_xXScreen labs of Hemoglobin, platelets, absolute neutrophil count (ANC), bilirubin, AST, ALT, serum creatinine, serum albumin, PT/INR, and PTT within specified values/criteria per protocol prior to dosing.Xx_NEWLINE_xXAcceptable hematology and serum biochemistry screening values: White Blood Cell Count (WBC) >= 1500/mm3; Absolute Neutrophil Count (ANC) >= 1,000/mm3; Platelet (PLT) count >= 75,000/mm3; Hemoglobin (HGB) >= 8 g/dl; Total bilirubin level <= 1.5 x institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x ULN; Creatinine <= 1.5 x ULN; Albumin > 25 g/LXx_NEWLINE_xXAdequate hematologic, hepatic, and renal function (absolute neutrophil count ?1.5x 109/L, Hgb >10 g/dL, platelet count ?100 x 109/L, AST/ALT ?2.5x ULN, creatinine ?1.5x ULN).Xx_NEWLINE_xXMarrow: Hemoglobin ?10.0 dm/dL, absolute granulocyte count (AGC)?1,000/mm^3, platelets ?100,000/mm^3, absolute lymphocyte count ?1000/mm^3.Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXSmall lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 109/L at the time of diagnosis and at study entryXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXLab criteria of absolute neutrophil count (ANC) >/= 1000 cells/mm3, platelets >/= 80,000 cells/mm3 if baseline bone marrow negative for TCL involvement and platelets >/= 20,000 cells/mm3 if baseline bone marrow positive for TCL involvement, bilirubin </= 2 x upper limits of normal (ULN) (Gilbert's </= 3 x ULN), creatinine </= 1.5 x ULN, and ALT and AST </= 3 x ULN.Xx_NEWLINE_xXPrior to day 1 of brentuximab vedotin, patients must again meet the following criteria:\r\n* Hemoglobin >= 8 g/dL\r\n* Absolute neutrophil count (ANC) >= 1,000 cells/mm^3\r\n* Platelet count >= 75,000/mm^3\r\n* Maximum Child-Pugh score of 5\r\n* Creatinine clearance > 50 mL/min via Cockcroft and GaultXx_NEWLINE_xXThe patient has an absolute neutrophil count (ANC) ?1000/µL, platelets ?100,000/µL and is not transfusion dependent for platelets and/or red cellsXx_NEWLINE_xXNeutrophil count ? 1,500 /mm3Xx_NEWLINE_xXNeutrophiles <1,500/mm3Xx_NEWLINE_xXLymphocyte count >= 400/mm^3Xx_NEWLINE_xXHas an absolute neutrophil count <1.0x10^9/L within 14 days before enrollmentXx_NEWLINE_xXPatients must meet the following laboratory criteria within 28 days of starting therapy: * Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L * Hemoglobin >/= 8 g/dl ( transfusion are permitted) * Platelet count > 70,000 cells/mm^3 for patients with < 50% of bone marrow plasma cells or platelet count > 25,000 cells/mm^3 for patients in whom > 50% of the bone marrow nucleated cells were plasma cells * aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) </= 2.5 x ULN * Serum bilirubin </= 2 x ULNXx_NEWLINE_xXAdequate hematologic status ANC >=1,500cells/mm3 Platelet Count >= 100,000cells/mm3 Hemoglobin >=9.0g/dLXx_NEWLINE_xXPatients should have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea or similar agent is allowed)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXAbsolute peripheral granulocyte count of >= 1,000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXCARBOPLATIN AND PACLITAXEL ARMS: absolute neutrophil count >= 1,500/mLXx_NEWLINE_xXSORAFENIB ARM: absolute neutrophil count >= 1,000/mLXx_NEWLINE_xXAbsolute lymphocyte count < 800/mm^3Xx_NEWLINE_xXPlatelet count > 100,000 cells/mm3, hemoglobin > 9 g/dL, absolute neutrophil count > 1,500 cells/mm3Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXNormal organ and marrow function as defined below: Absolute granulocyte count ? 1,500/mm3 Absolute lymphocyte count ? 500/mm3 Platelets ? 100,000/mm3 Total bilirubin ?2 mg/dL AST(SGOT)/ALT(SGPT) <2x institutional upper limit of normal Creatinine <1.5 mg/dLXx_NEWLINE_xXAdequate hematologic status ANC >=1,500cells/mm3 Platelet Count >=100,000cells/mm3 Hemoglobin >=9.0g/dLXx_NEWLINE_xXLymphocyte count less than or equal to 4,000/mm^3Xx_NEWLINE_xXBone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ? 1000/µl, platelet count ? 100,000/µl (transfusion independent) and hemoglobin ? 8.0 gm/dLXx_NEWLINE_xXPatients should have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea or similar agent is allowed)Xx_NEWLINE_xXMinimum absolute neutrophil count of 1,000 cells/ul and minimum platelet count (without transfusion) of 20,000/mm^3; values below these levels may be accepted at the discretion of the PI, if thought to be due to bone marrow involvement by malignancyXx_NEWLINE_xXAdequate bone marrow, liver & renal function as assessed by the following laboratory requirements to be conducted w/in 7 days prior to start of first dose: Hemoglobin >/= 9.0 g/dL; Absolute neutrophil count (ANC) >/= 1,500/mm^3; Platelet count >/= 100,000/mm^3; Total bilirubin </= 1.5 times the upper limit of normal (ULN);ALT and AST </= 2.5 x ULN (</= 5 x ULN for pts w/ liver involvement); INR </= 1.5 and PTT w/in normal limitsXx_NEWLINE_xXPersistent, unexplained increases in absolute eosinophil count prior to initiation of vaccineXx_NEWLINE_xXNo unexplained absolute eosinophil count > 1.5x10^9/LXx_NEWLINE_xXNeutrophil count > 1,000/mm3Xx_NEWLINE_xXFor Phase 1b individuals: absolute lymphocyte count (ALC) > 5000/?L in peripheral blood.Xx_NEWLINE_xXAbsolute neutrophil count ? 1,000 cells/mm3Xx_NEWLINE_xXGroup 4: Patients who meet group 1 inclusion criteria but may have FVC or DLCO-adjusted less than 70% plus have had an adverse event on cyclophosphamide preventing its further use (specifically hemorrhagic cystitis, leukopenia with white blood cell [WBC]< 2000 or absolute neutrophil count [ANC] < 1000 or platelet count < 100,000)Xx_NEWLINE_xXAbsolute leukemic blast count in peripheral blood >50,000/ microliter;Xx_NEWLINE_xXAdequate bone marrow function (hemoglobin ? 9.0 g/dL; platelets ? 75 x10^9 cells/L; absolute neutrophil count ? 1.0x10^9 cells/L).Xx_NEWLINE_xXSmall lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 10^9/L at the time of diagnosisXx_NEWLINE_xXLymphocyte count 500/mLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/mm^3 (without platelet transfusion or myeloid growth factor support within two weeks of screening)Xx_NEWLINE_xXAdequate bone marrow function (hemoglobin ? 9.0 g/dL; unsupported platelets ? 100×109 cells/L; absolute neutrophil count [ANC] ? 1.5×109 cells/L without the use of hematopoietic growth factors)Xx_NEWLINE_xXAbsolute neutrophil count < 1,500/?L, platelet count < 75,000/?L, or hemoglobin < 5.6 mmol/L (9 g/dL) at screening.Xx_NEWLINE_xXSubjects must have adequate bone marrow function as assessed by the following: hemoglobin >=9.0 g/dL or >=5.6 mmol/L, absolute neutrophil count (ANC) >=1.500/mm^3 or >=1.5 x 10^9/L (CTCAE Grade <=1), platelet count >= 100000/mm^3 or >=100 x 10^9/LXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.5 unless cytopenias are related to bone marrow involvement with diseaseXx_NEWLINE_xXCirculating blast count >= 50,000/uL within the week preceding enrollmentXx_NEWLINE_xXAdequate bone marrow function (hemoglobin ?9.0 g/dL; platelets ?100 x10^9 cells/L; absolute neutrophil count ?1.5x10^9 cells/L) without the use of hematopoietic growth factors.Xx_NEWLINE_xXWBC count <25,000 cells/mm3 (25 x 109/L)Xx_NEWLINE_xXPersistent cytopenia requiring growth factors and/or blood products AND evidence of hypocellular BM (< 25%); persistent cytopenia (at least 4 week period) is defined by presence of TWO of the following:\r\n* Absolute neutrophil count (ANC) < 1.0 x 10^9/L without filgrastim support or any ANC value that requires recurrent support by filgrastim (administered at least once a week)\r\n* Platelets (Plt) < 50 x 10^9/L\r\n* Hemoglobin (Hb) < 8 or packed red blood cell (PRBC) transfusion dependent (once every 2 weeks or more) with reticulocyte count of < 40 x 10^9\r\n* This criteria for persistent cytopenia and hypocellular bone marrow does not apply to patients with auto-immune cytopenia ONLY PGF patientsXx_NEWLINE_xXHematologic function: Absolute neutrophil count (ANC) > 500/?L and platelet count > 25,000/?L without transfusionXx_NEWLINE_xXAbsolute CD4+ lymphocyte count: >= 75 cells/uLXx_NEWLINE_xXAdequate bone marrow function [absolute neutrophil count (ANC) > 1,500/mm3 & platelet count of > 100,000/mm3], adequate liver function [alanine aminotransferase (ALT) & aspartate aminotransferase (AST) <3 x upper limit normal (ULN), alkaline phosphatase <2 x ULN, & total bilirubin <1.5 mg/dL], & adequate renal function (BUN & creatinine <1.5 x ULN)Xx_NEWLINE_xXInadequate bone marrow function (Absolute neutrophil count (ANC) < 1,500 cells/mm3; Platelet count < 100,000 cells/mm3; Hemoglobin < 9.0 g/dL)Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 0.5 X 10^9/LXx_NEWLINE_xXPlatelet count >/=100,000 /mm3, hemoglobin >/=9 g/dL, absolute neutrophil count >/= 1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factorsXx_NEWLINE_xXAbsolute neutrophil count (ANC) must be > 750/mm^3 (unless due to underlying disease in which case there is no grade restriction)Xx_NEWLINE_xX12. Adequate bone marrow function (hemoglobin ? 9.0 g/dL; platelets ? 100 x 109/L; absolute neutrophil count [ANC] ? 1.5 x 109/L) without the use of hematopoietic growth factors.Xx_NEWLINE_xXAdequate bone marrow function (hemoglobin ? 9.0 g/dL; unsupported platelets ? 100 x10 9 cells/L; absolute neutrophil count ? 1.5x10 9 cells/LXx_NEWLINE_xXPlatelet count ? 100,000 plts/mm3 (without transfusion); ? 75,000 plts/mm3 for patients with hepatocellular carcinoma only. For hematologic malignancy patients blood counts cited above do not applyXx_NEWLINE_xXThe following laboratory parameters must be within the ranges specified: Hemoglobin ? 10 g/dL, Neutrophil count ? 1.5 x 109/L, Lymphocyte count ? LLN Platelet count ? 80 x 109/L, Serum creatinine ? 2 mg/dL, Serum bilirubin ? 2 x ULN, AST/ALT ? 2 x ULN.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 109/L)Xx_NEWLINE_xXPlatelet count > 50,000 cells/dL (50 x 109/L)Xx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 200/?LXx_NEWLINE_xXTotal lymphocytes count ? 0.5x10E9/LXx_NEWLINE_xXAbsolute granulocyte count (AGC) >= 2000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 x 10^9/L unsupported by G-CSF or GM-CSF for 10 days or Neulasta for 21 days; the hematologic requirements are waived for patients with inadequate counts due to known bone marrow involvement by disease who are otherwise eligibleXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Absolute neutrophil count >= 1,000/mm^3Xx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Absolute neutrophil count >= 1,000/mm^3Xx_NEWLINE_xXLymphocyte count >= 300/mcLXx_NEWLINE_xXAbsolute neutrophil count >1200/mm3, hemoglobin (Hb) ?10 g/dL and platelets ?100,000/mm3Xx_NEWLINE_xXAbsolute neutrophil count > 1.5 x 10^9 cells/mm^3, +/- 7 days from date of ICF signingXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,500 cells/mm3 or ? 1000 cells/mm3 if secondary to bone marrow involvement by disease.Xx_NEWLINE_xXPlatelet count ? 100,000 cells/mm3 (100 x 109/L) or ? 50,000 cells/mm3 (50 x 109/L) if secondary to bone marrow involvement by disease.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) less than 1,000 /mm3Xx_NEWLINE_xXPlatelet count ? 100 x 109/L, absolute neutrophil count (ANC) ? 1.5 x 109/L, Hemoglobin ? 9 g/dL.Xx_NEWLINE_xXLeukocyte count <3000/µL,Xx_NEWLINE_xXLymphocyte count <1000/µL,Xx_NEWLINE_xXAbsolute neutrophil count ? 1,500/mm3 (not supported by growth factors in the preceding 21 days);Xx_NEWLINE_xXHemoglobin ? 7.5 g/dL, - Absolute neutrophil count ? 1.0 x 109/L (1000/mm3), - Platelets ? 50,000/?LXx_NEWLINE_xXPeripheral blood blast count must be ? 30,000 cells/µL.Xx_NEWLINE_xXLymphoma participants without bone marrow involvement must have: \r\n* Absolute neutrophil count (ANC) >= 1,000/µL, and\r\n* Platelet count > 50,000/mm^3 (without transfusion support)\r\n** Note: these criteria are waived for participants with leukemia or lymphoma participants with bone marrow involvementXx_NEWLINE_xXAbsolute lymphocyte count (ALC) ? 1,000/?l (? 500/?l after stem cell transplant) Note: After completion of dose escalation, patients with AML are not required to meet these hematologic criteria.Xx_NEWLINE_xXAdequate bone marrow reserve: ANC ?1500/mm3, platelets ?100,000/mm3Xx_NEWLINE_xXSmall lymphocytic lymphoma (SLL) with absolute lymphocyte countXx_NEWLINE_xXHematologic: Platelets ? 100 x 10^9/L; Hemoglobin ? 9.0 g/ dL; Absolute neutrophil count (ANC) ? 1.5 x 10^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit). Patients in the Group 3 lymphoma expansion may be enrolled with an ANC of ? 1.0 x 10^9 /L; Platelets ? 75 x 10^9 /L.Xx_NEWLINE_xXSubject has absolute neutrophil count < 1000/?L, platelet count < 75,000/?L, and hemoglobin < 8 g/dL (< 5 mmol/L) at ScreeningXx_NEWLINE_xXAdequate bone marrow function (subjects other than those with AITL) as evidenced by: absolute neutrophil count ?1.0 ×109/L;hemoglobin >9 g/dL (Subjects may be transfused red blood cells to this level.); platelets ?50 × 109/LXx_NEWLINE_xXWBC count ? 3.0 x 103 cells/µLXx_NEWLINE_xXLymphocyte count ? 0.8 x 103 cells/µLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL (unless due to lymphoma involvement of the bone marrow)Xx_NEWLINE_xXGranulocyte count >= 1,500/mm^3 within 16 days of starting therapyXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testingXx_NEWLINE_xXAbsolute neutrophil count >=1,500 per cubic millimeter (/mm^3), not supported by growth factorXx_NEWLINE_xXPatients should have adequate bone marrow function defined as a peripheral WBC >3,000/mm3 with an ANC >1500/mm3 and a platelet count >100,000/mm3.Xx_NEWLINE_xXHematologic: Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, hemoglobin ? 9 g/dL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. The first dose of study drug must not begin until 5 days after the erythrocyte transfusion);Xx_NEWLINE_xXLaboratory values: screening serum creatinine > 1.5xULN, ALT > 2.5xULN, total bilirubin > 1.5xULN, ANC < 1500/mm3, platelet concentrations < 100,000/mm3, absolute lymphocyte count < 1000/mm3, hematocrit level < 27% for females or < 30% for males, serum albumin ? 2.5 g/dL, PT/INR 1.5xULN or >3xULN on anticoagulant with no evidence of active bleeding.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ³ 1.5 × 109/L (1,500/mm3)Xx_NEWLINE_xXDoes the subject have an absolute lymphocyte count ? 500/mm3?Xx_NEWLINE_xXAdequate baseline hematological parameters as defined by white blood cell count (WBC) ? 3.5 x 103/µL, lymphocyte count ? 1.0 x 103/µL, platelet count ? 100 x 103/µL, and hemoglobin ? 9 g/dLXx_NEWLINE_xXPlatelet count ? 100,000/cubic millimeters (mm3), hemoglobin (Hb) ? 8.5 g/dl, leukocyte count > 3,000/mm3, absolute neutrophil count (ANC) ? 1,000/mm3Xx_NEWLINE_xXAdequate hematologic function including ANC ? 1200/mm3, Hemoglobin ? 9 g/dL (transfusion is permitted), and platelets ? 100,000/mm3.Xx_NEWLINE_xXAbsolute Neutrophils Count (ANC) ? 1.5 x 109/LXx_NEWLINE_xXHematology: ANC >1500 cells/mm3, platelet count > 150,000 cells/mm3 and Hemoglobin > 9 g/dLXx_NEWLINE_xXTotal white blood cell count (WBC) ? 3000/µl, or absolute neutrophil count (ANC) ? 1000/µlXx_NEWLINE_xXAbsolute lymphocyte count ?0.75 x 10^3/µlXx_NEWLINE_xXBone Marrow: Absolute neutrophil count ANC ? 1,500/mm3 (1.5 × 109/L); Platelets ? 100,000/mm3 (100 × 109/L); Hemoglobin ? 9.5 g/dL (1.4 mmol/L). Subjects with hemoglobin ? 9.5 g/dL (1.4 mmol/L) following transfusion are eligible;Xx_NEWLINE_xXAbsolute Neutrophil count (ANC) ? 1.0 x 109/L without daily use of myeloid growth factor; andXx_NEWLINE_xXAbsolute neutrophil count of =< 1.0 x 10^9/L less than 7 days before enrollment; use of growth factors is permitted to fulfill this criterion, but should be discussed on a case-by-case basis with the study PI and permission will depend on etiology of the neutropenia, if not felt to be due to MMXx_NEWLINE_xXabsolute neutrophil count >1,000/?L in absence of bone marrow involvementXx_NEWLINE_xXAbsolute neutrophil count ?1,000/µL (unless due to documented leukemic involvement of the bone marrow at the time of study entry)Xx_NEWLINE_xXAbsolute neutrophil count < 1,000/?L, platelet count < 75,000/?L, and hemoglobin < 9 g/dL (NOTE: subject may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the Screening visit)Xx_NEWLINE_xXHemoglobin ? 8.5 mg/dl 14. Absolute neutrophil count ? 1.5 x 10^9/L 15. Platelets ? 75 x 10^9/L 16. Life expectancy ? 3 monthsXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,200; patients with bone marrow involvement are allowed at the investigator’s discretion regardless of cytopeniasXx_NEWLINE_xXGranulocyte count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count ? 500/µL, with or without cytokine supportXx_NEWLINE_xXPlatelet count ? 50,000/µL, with or without transfusion support; platelet count < 50,000/µL but ? 20,000/µL, with or without transfusion support, is permissible if the subject has not had Grade ? 2 bleeding in the prior 6 months (where grading of the bleeding is determined per the National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE], version 5.0)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mLXx_NEWLINE_xXAbsolute neutrophil count >/= 1,200/mm3Xx_NEWLINE_xXAbsolute neutrophil count >= 1,200/µLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/dL (1.0 x 10^9/L) (growth factors cannot be used within 7 days of first drug administration)Xx_NEWLINE_xXFor patients enrolled into Stage I, they must have received at least 75% of planned radiotherapy (60 Gy) with temozolomide treatment during the concomitant phase have documentation that the patient's absolute neutrophil count (ANC) is ? 1.5 x 109/L, platelet count is ? 100 x 109/L, and there was no CTC grade 2 or above nonhematological toxicity (except for alopecia, nausea, vomiting) during the concomitant phase treatment be within ? 4 weeks but ? 6 weeks following the completion of temozolomide in the concomitant phaseXx_NEWLINE_xXAbsolute lymphocyte count lower than 200 x 10^9/l .Xx_NEWLINE_xXAbsolute Neutrophil Count < 1.000/µl.Xx_NEWLINE_xXBone marrow: Absolute Neutrophil Count (ANC) ? 1.5 x 109/L, Hemoglobin (Hgb) ? 9 g/dL, Platelets ? 100 x 109/LXx_NEWLINE_xXAbsolute granulocyte count >= 1.5 x 10^9/LXx_NEWLINE_xXAbsolute lymphocyte count >= 200/mm^3Xx_NEWLINE_xXInadequate blood countXx_NEWLINE_xXThe participant has adequate hematologic function as defined by absolute neutrophil count ? 1500/microliters (?L), hemoglobin ? 9 gram/deciliter (g/dL), and platelet count ?100,000/?LXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000/µL (1.0 x 109/L)Xx_NEWLINE_xXPlatelets > 100,000/mm3 and WBC > 3000/mm3.Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/mcL independent of growth factor supportXx_NEWLINE_xXPlatelet count >= 100,000/mm3 independent of transfusion support OR >= 50,000/mm3 independent of transfusion\r\nsupport if bone marrow involvementXx_NEWLINE_xXNeutrophil count ? 1,000/mm3Xx_NEWLINE_xXLymphocyte count ? 500/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000/mm^3 (International System of Units [SI] units 109/L)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.5 x 10^9/L (growth factor support is allowed to reach this goal)Xx_NEWLINE_xXCD4 lymphocyte count is highly encouragedXx_NEWLINE_xXNeutropenia (absolute neutrophil count < 1.0 x 10^9/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) persistently >= 1500/mm^3 (as measured by 3 complete blood counts [CBCs] done over 6 weeks or 2 successive monthly CBCs) despite 6?MP >= 150% of Children’s Oncology Group (COG) dosingXx_NEWLINE_xXBone marrow reserve: absolute neutrophil count (ANC) >=1000/microliter (?L), platelet count >=75,000/?L (>=50,000/?L for participants with bone marrow involvement), and hemoglobin >=8 gram per deciliter (g/dL).Xx_NEWLINE_xXAbsolute neutrophil count ? 1500 per microliter Stages I and II, Arm C or Stage II Arm D:Xx_NEWLINE_xXAdequate bone marrow reserve: absolute neutrophil count (ANC) greater than or equal to (>=) 1000 per micro litre (/mcL), platelet count >=75,000/mcL (>=50,000/mcL for participants with bone marrow involvement), and hemoglobin >=8 gram per deciliter (g/dL) (red blood cell [RBC] and platelet transfusion allowed >=14 days before assessment).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,000 cells/mm3Xx_NEWLINE_xXMust have achieved neutrophil engraftment (defined as an absolute neutrophil count [ANC] > 500 for three consecutive days) and be off daily filgrastim (G-CSF) prior to starting romiplostim; intermittent G-CSF is allowedXx_NEWLINE_xXAbsolute neutrophil count less than 200/microliterXx_NEWLINE_xXBlast count ?20%Xx_NEWLINE_xXHave a circulating blast count of less than 200/mm3 (control with hydroxyurea or similar agent is allowed);Xx_NEWLINE_xXScreening blood counts of the following: Absolute neutrophil count ? 1000/?L, Platelets ? 75,000/?L, Hemoglobin ? 8 g/dL (with transfusion support);Xx_NEWLINE_xXAbsolute neutrophil count ?1.0 × 10^9/Liter, hemoglobin ?9 grams/deciliter, and platelets ?75 × 10^9/Liter.Xx_NEWLINE_xXHematopoietic engraftment as evidenced by recovery of the absolute neutrophil count to greater than 500/mm^3 for > 3 days without filgrastim (G-CSF) support and within 40 days of transplant (i.e. complete blood counts [CBCs] obtained 3 or more days apart while off of G-CSF must demonstrate an absolute neutrophil count > 500/mm^3); if absolute neutropenia is not achieved due to a non-myeloablative transplant, the patient can be enrolled on day +21 to +40Xx_NEWLINE_xXNeutropenia (absolute neutrophil count < 1.0) (bloodwork is not required if patient did not have recent chemotherapy within last 2 weeks)Xx_NEWLINE_xXImmune compromised or other serious medical conditions, other than cancer diagnostic, at enrollment; immune compromised subjects will be defined as having absolute neutrophil count (ANC) less than 1000 as determined by complete blood count testing (CBD) performed weekly as standard of care in individuals receiving chemoradiationXx_NEWLINE_xXAnticipated or documented prolonged neutropenia (absolute neutrophil count [ANC] < 500/mm^3 [0.5 x 10^9/L]) at baseline or likely to develop within 3 to 5 days and lasting for at least 7 days due to:Xx_NEWLINE_xXANC ? 1,000/?LXx_NEWLINE_xXLymphocyte count >= 800/mm^3 within 90 days of enrollmentXx_NEWLINE_xXPatients must have or be anticipated to have neutropenia (absolute neutrophil count [ANC] < 0.5 x 10^9/L) (75) for >= 7 days as a result of treatment of their AML/MDSXx_NEWLINE_xXRequired prior to infusion of ATLCAR.CD30 cells: Platelet count >= 25,000 cells/mm^3 without transfusion over preceding 5 daysXx_NEWLINE_xXAML, ALL\r\n* Normal values for absolute neutrophil count (> 1000/microL) and platelet count (> 100,000/microL)\r\n* Absence of extramedullary leukemia\r\n* Less than 5 percent blast cells present in the bone marrowXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/microliterXx_NEWLINE_xXLeukocyte count >= 3,000/microliterXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/microliter obtained =< 45 days prior to randomizationXx_NEWLINE_xXAbsolute Neutrophil Count (ANC) ? 1.5 x 109/L or ? 1.0 x 109/L (with bone marrow involvement with DLBCL)Xx_NEWLINE_xXSubjects must have the following laboratory values: Absolute Neutrophil Count (ANC) ? 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim).Xx_NEWLINE_xXAbsolute lymphocyte count ? 500/mm3Xx_NEWLINE_xXHas baseline neutrophil counts of > 1500 cells/mm3 within 72 hours prior to registrationXx_NEWLINE_xXTotal granulocyte count of > 1.5 x 10^9/LXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.5 X 10^9/L without (w/o) myeloid growth factor support for 7 days preceding lab assessment, obtained within 14 days prior to PET scanXx_NEWLINE_xXAbsolute neutrophil count ?1.50 x 109/LXx_NEWLINE_xXAbsolute neutrophil count (ANC) ?1.5 x 109/L (in absence of growth factor support)Xx_NEWLINE_xXBone marrow function: neutrophil count >/=1,000/mm3, platelet count >/= 75,000/mm3 and hemoglobin concentration >/= 8.0 g/dL.Xx_NEWLINE_xXBaseline safety laboratory abnormalities: ANC (absolute neutrophil Count) < 1000 cells/mm3, platelet count < 25,000 cells/mm3, hemoglobin < 8.0 g/dL, AST (aspartate transaminase) or ALT (alanine transaminase) > 5 x ULN (upper Limit of normal), bilirubin > 2.5 x ULNXx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/mm^3 (1.0 x 10^9/L), unless they have significant bone marrow involvement of their malignancy confirmed on biopsy, completed within 2 weeks prior to start of protocol therapy; growth factor allowed to achieveXx_NEWLINE_xXSustained platelet count ?50,000/µL, and/or sustained Hgb ?8 g/dL and/or sustained ANC ?1000/mm3, which is considered by the Investigator as related to the nature of the graft (higher transient levels following occasional blood product transfusions are allowed).Xx_NEWLINE_xXAcceptable laboratory results during screening and prior to first study drug administration of the following parameters: absolute neutrophil count (ANC), platelet count, hemoglobin, total bilirubin, aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT), renal function based on estimated creatinine clearanceXx_NEWLINE_xXAbsolute neutrophil count > 750Xx_NEWLINE_xXPatients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of > 1,500 /mm3 and platelet count >100,000/mm3 along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trialXx_NEWLINE_xXAdequate bone marrow function, defined as an absolute neutrophil count (ANC) of greater than or equal to (>=) 1.5*109 per liter (/L), platelet count >=100*109/L, and hemoglobin >=9 gram per deciliter (g/dL). Receiving transfusions or hematopoietic growth factors to meet enrollment criteria is not allowed within 14 days preceding the first dose of study drug.Xx_NEWLINE_xXANC ? 1500 mm3, platelets ? 100,000/mm3, hemoglobin ? 9 g/dL,Xx_NEWLINE_xXNeutrophil count <1.5 x 109/LXx_NEWLINE_xXAdequate bone marrow reserve: absolute neutrophil count (ANC) greater than or equal to (>=) 1000 per cubic millimeter (/mm^3), platelet count >=75,000/ mm^3 (>=50,000 per micro liter (/mcL) for participants with bone marrow involvement), and hemoglobin >=8 gram per deciliter (g/dL) (red blood cell [RBC] transfusion allowed >=14 days before assessment).Xx_NEWLINE_xXAbsolute neutrophils count (ANC) ? 1.5 x 10E9/L, platelets ? 100 x 10E9/L, hemoglobin > 9 g/dL (without transfusion or erythropoiesis stimulating agents dependency).Xx_NEWLINE_xXHemoglobin must be >=8 gram per deciliter (g/dL), absolute neutrophil count (ANC) must be >=1500 per microliter (/mcL), and platelet count must be >=75,000/mcL.Xx_NEWLINE_xXAbsolute Neutrophils > 1.5 x 109/LXx_NEWLINE_xXAbsolute blast count ?10,000/mm3 or symptoms of leukostasisXx_NEWLINE_xXAbsolute neutrophil count >= 500 /uL (absolute neutrophile count [ANC] values in accordance with ongoing ibrutinib studies for patients with CLL), unless cytopenias are due to bone marrow highly infiltrated with CLL cells, e.g. > 80%Xx_NEWLINE_xX